GlassScriptPhysician profile
Amar S Bukhari
NPI 1518917822
$20,954.14
in general payments reported to CMS, 2019-2025
26 companies · $3,501 in 2025
The $3,501 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $28.79 · 2021: $53.39 · 2022: $389 · 2023: $9,971 · 2024: $6,491 · 2025: $3,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $3,905 · Food and Beverage: $1,875 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,125.00 |
| Travel and Lodging | $3,905.20 |
| Food and Beverage | $1,874.59 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $15,353.35 | 2023-2024 | Arrow |
| Intuitive Surgical, INC. | $3,231.13 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $541.38 | 2021-2025 | Tezspire, Breztri, Lokelma |
| Genzyme Corporation | $407.20 | 2022-2025 | |
| Glaxosmithkline, LLC. | $180.60 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Harmony Biosciences LLC | $169.22 | 2022-2024 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.07 | 2019-2024 | Ofev |
| Sanofi-Aventis U.S. LLC | $153.98 | 2022-2024 | |
| Covidien LP | $137.20 | 2019 | |
| Philips North America LLC | $109.77 | 2019-2024 | (Ak6) Vest Therapy |
| Penumbra, INC. | $107.59 | 2025 | Indigo System |
| Inspire Medical Systems, INC. | $71.11 | 2023-2025 | Inspire |
| Pulmonx Corporation | $42.50 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| La Jolla Pharmaceutical Company | $38.54 | 2019 | |
| Boston Scientific Corporation | $37.24 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $35.95 | 2022-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $28.43 | 2019 | |
| Merck Sharp & Dohme LLC | $26.75 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.96 | 2019 | |
| United Therapeutics Corporation | $18.90 | 2024 | Tyvaso |
| Verona Pharma, INC. | $18.59 | 2025 | Ohtuvayre |
| Amgen INC. | $16.71 | 2024 | Tezspire |
| Resmed Corp | $16.04 | 2020 | |
| Circassia INC. | $14.77 | 2019 | |
| Electromed, INC. | $14.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Bukhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.